We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Patients requiring treatment outside of hospitals will be able to choose between multiple providers across the NHS and independent sector.
A new pathway supporting innovative approaches to the safe, timely and efficient development of medicines to improve patient access.
The MHRA has today set out its strategic approach to artificial intelligence (AI)
How to use a patient-reported outcomes and experiences study to evaluate your digital health product.
Past and current clinical trials into therapeutic and antiviral treatments for COVID-19, how to take part, and which treatments have proven to be effective.
How to package medicines for sale and what information you must provide to consumers and healthcare professionals.
This toolkit is for Innovation Passport holders following the Innovative Licensing and Access Pathway (ILAP) and provides activities to support the design and development of medicines.
The government’s plans for the NHS and social care to deliver for patients, this winter and next.
Guidance, key documents, and CMA decisions on the review of PPU arrangements under the Private Healthcare Market Investigation Order 2014.
New features in the NHS App improve patient experience and support elective care recovery, as well as helping reduce ongoing pressure on the health service.
New tool uses artificial intelligence to assess hospital data and help predict patients at risk of becoming long stayers, with resulting negative implications.
Safety leaflet on opioid medicines to help patients and their families reduce the risks of harm.
Actions that trial sponsors should consider to build resilience into clinical trial design
Patients will be given more choice and greater control over their own care, including through the NHS App.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).